⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGVN News
Longeveron Inc. Common Stock
Form 8-K
sec.gov
LGVN
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN
Form 8-K
sec.gov
LGVN
Longeveron® Appoints Marie Washburn as Chief Financial Officer
globenewswire.com
LGVN
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
globenewswire.com
LGVN
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN